Biogen
BIIB
1,020 hedge funds and large institutions have $51.5B invested in Biogen in 2017 Q1 according to their latest regulatory filings, with 91 funds opening new positions, 389 increasing their positions, 395 reducing their positions, and 84 closing their positions.
8% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 84
0.1% more ownership
Funds ownership: 87.09% → 87.2% (+0.1%)
1% less funds holding
Funds holding: 1,026 → 1,020 (-6)
2% less repeat investments, than reductions
Existing positions increased: 389 | Existing positions reduced: 395
4% less capital invested
Capital invested by funds: $53.7B → $51.5B (-$2.23B)
25% less call options, than puts
Call options by funds: $811M | Put options by funds: $1.08B
34% less funds holding in top 10
Funds holding in top 10: 41 → 27 (-14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.83B |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$368M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$366M |
| 4 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$357M |
| 5 |
Goldman Sachs
New York
|
+$125M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$752M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$482M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$348M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$170M |
| 5 |
Two Sigma Investments
New York
|
-$158M |
BIIB Hedge Fund Activity: Q1 2017 in Review
1,020 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2017, worth a combined $51.5B — down 4.1% from $53.7B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new BIIB positions and 84 closed out — a net gain of 7 holders — while 389 added to existing stakes and 395 trimmed.
The largest buyer was BlackRock, adding an estimated $4.83B. The largest seller was Fidelity Investments, cutting an estimated $752M.
- 1,020 institutional investors held Biogen (BIIB) as of Q1 2017, down from 1,026 in Q4 2016.
- Funds reported $51.5B of Biogen stock for Q1 2017, down 4.1% quarter-over-quarter.
- 91 funds opened new Biogen positions in Q1 2017 and 84 closed out, a net change of +7 holders.
- The largest Biogen buyer in Q1 2017 was BlackRock, an estimated $4.83B added.
- The largest Biogen seller in Q1 2017 was Fidelity Investments, an estimated $752M sold.
Based on aggregated 13F filings for Q1 2017.